• Science and Research

  Path BioAnalytics Licenses Cavosonstat From Laurel Therapeutics

  Posted by cystic-fibrosis-news-moderator on August 26, 2019 at 7:04 pm

  

  Path BioAnalytics has licensed the rights to further develop cavosonstat, a targeted therapy for cystic fibrosis, from Chinese company Laurel Therapeutics. Click here to read more.

  What do you think of this information?

  cystic-fibrosis-news-moderator replied 4 years, 8 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply